Souhaitez-vous accéder aux communiqués récents ?

A Registrational Phase 2 clinical trial has been initiated in Japan for patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE)...

Memorial Sisli Hospital’s Nuclear Medicine Department has been recognized as an EARL-qualified Theranostics Center of Excellence by EANM.

Louvain-la-Neuve, Belgique, le 19 décembre 2025 - IBA (Ion Beam Applications S.A., EURONEXT), leader mondial des technologies d’accélération de particules et acteur de premier plan en médecine...

Louvain-La-Neuve, Belgium, 19 December 2025 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology with a preeminent position in nuclear medicine, acquires...

Curium has established a legal entity in China which represents a major milestone in Curium’s international growth strategy and will enhance Curium’s ability to serve patients with cancer across...

Curium and CapVest have announced the recapitalization of Curium via a new Continuation Vehicle The transaction values Curium at circa $7 billion, representing the largest transaction in nuclear...

Curium has entered a partnership with the Czech company ÚJV Řež, a leading expert in the development and production of radiopharmaceuticals, to manufacture diagnostic radiopharmaceuticals for patients...

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Algernon Health Inc. (the “Company” or...

Dublin, Oct. 16, 2025 (GLOBE NEWSWIRE) -- The "Nuclear Medicine Equipment Market - A Global and Regional Analysis: Focus on Application, End User, Country, and Region - Analysis and Forecast,...

Kay was instrumental in driving the successful development and commercialization of Xofigo®, the first and only approved alpha therapy to date SYDNEY, Australia - October 16, 2025 – AdvanCell, a...